Avanos Medical (AVNS) Common Equity (2013 - 2026)

Avanos Medical's Common Equity history runs 14 years deep, the most recent figure standing at $782.1 million for Q1 2026.

• In Q1 2026, Common Equity fell 6.83% year-over-year to $782.1 million; the TTM figure through Mar 2026 stood at $782.1 million (down 6.83% YoY), while the FY2025 annual figure was $778.2 million, down 53.64% from the prior year.
• Common Equity came in at $782.1 million for Q1 2026 at Avanos Medical, up from $778.2 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $1.7 billion in Q4 2024 to a low of -$315.8 million in Q1 2024.
• A 5-year average of $711.9 million and a median of $782.1 million in 2026 frame the typical range for Common Equity.
• Across the five-year window, Common Equity tumbled 365.1% in 2024 and jumped 365.8% in 2025, its largest moves.
• Avanos Medical's Common Equity stood at $1.3 billion in 2022, then slipped by 4.25% to $1.2 billion in 2023, then surged by 35.78% to $1.7 billion in 2024, then sank by 53.64% to $778.2 million in 2025, then advanced by 0.5% to $782.1 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $782.1 million, $778.2 million, and $778.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison